Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT06096025

Short Versus Long Duration of Therapy for Streptococcus Pneumoniae Bloodstream Infections

Short Versus Long Duration of Therapy for Streptococcus Pneumoniae Bloodstream

Status
Active Not Recruiting
Phase
Study type
Observational
Enrollment
200 (estimated)
Sponsor
Methodist Health System · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers

Summary

Streptococcus pneumoniae is a gram-positive (GP) bacteria responsible for common infections such as community-acquired pneumonia (CAP), as well as complicated infections such as bacteremia, infective endocarditis and meningitis. S. pneumoniae bacteremia ranks among the top 10 most common pathogens associated with bloodstream infections and correlates with high morbidity and mortality worldwide.

Detailed description

The Infectious Diseases Society of America (IDSA) guidelines for CAP management advocate for short courses of antibiotics for CAP treatment. However, it does not address duration of therapy for common CAP pathogens such as S. pneumoniae when associated with blood stream infections (BSI). 3 Currently, GP bacteremia duration of therapy typically ranges from 7 to 14 days based on IDSA guideline recommendations for Staphylococcus aureus bacteremia with no further definitive consensus.4 Additionally, lack of data and randomized clinical trials on the efficacy and safety of short compared to long treatment duration have led to variability in practice. Most randomized clinical trials as well as retrospective studies on treatment duration, have been conducted mainly in gram-negative BSI

Conditions

Interventions

TypeNameDescription
DRUGpneumoniae bacteremia therapyTo evaluate the effectiveness of short 10 days versus long (≥10 days) duration of therapy associated with S. pneumoniae bacteremia.

Timeline

Start date
2023-06-23
Primary completion
2026-06-23
Completion
2026-06-23
First posted
2023-10-23
Last updated
2025-07-04

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT06096025. Inclusion in this directory is not an endorsement.